CRISPR Therapeutics AG
Income Statement
| Line Item | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $158.0K | $940.0K | $12.9M | $824.0K | $900.7M | $539.0K | $370.0K | $148.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $123.2M | $118.2M | $104.1M | $83.5M | $82.3M | $70.6M | $36.8M | $71.0M |
| SG&A Expense | $26.3M | $28.0M | $22.7M | $23.7M | $28.8M | $24.5M | $23.3M | $21.5M |
| Operating Income | $-183.3M | $-176.0M | $-145.7M | $-128.8M | $762.6M | $-114.5M | $-107.8M | $-92.4M |
| Operating Margin | -115,987.3% | -18,720.4% | -1,129.5% | -15,637.0% | 84.7% | -21,251.0% | -29,124.6% | -62,431.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-179.7M | $-175.6M | $-143.5M | $-127.7M | $763.4M | $-112.6M | $-107.2M | $-92.2M |
| Income Tax Expense | $6.1M | $3.6M | $-2.3M | $-595.0K | $4.1M | $575.0K | $-147.0K | $200.0K |
| Net Income | $-185.8M | $-179.2M | $-141.2M | $-127.2M | $759.2M | $-113.2M | $-107.0M | $-92.4M |
| Net Margin | -117,616.5% | -19,065.6% | -1,095.0% | -15,431.2% | 84.3% | -20,995.0% | -28,929.5% | -62,458.8% |
| EPS (Basic) | $-2.40 | $-2.32 | $-1.86 | $-1.67 | $10.01 | $-1.51 | $-1.50 | $-1.32 |
| EPS (Diluted) | $-2.40 | $-2.32 | $-1.56 | $-1.67 | $9.44 | $-1.51 | $-1.50 | $-1.32 |
| Shares Outstanding (Basic) | 77.5M | 77.1M | 75.9M | 76.3M | 75.8M | 75.0M | 71.3M | 70.1M |
| Shares Outstanding (Diluted) | 77.5M | 77.1M | 80.4M | 76.3M | 80.4M | 75.0M | 71.3M | 70.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |